Stocks
Health Care
halo
Halozyme Therapeutics
NASDAQ: HALO
+0.38 (+0.59%)
64.415
USD
At close at Aug 13, 19:06 UTC
Income Statement
Revenue
1.02B
Gross Profit
855.91M
Operating Income
551.48M
Pretax Income
604.93M
Net Income
444.09M
EBITDA
656.54M
EBIT
575.23M
Earnings Per Share
3.5
Balance Sheet
Cash & Cash Equivalents
155.66M
Total Debt
1.50B
Net Cash
-
Net Cash Per Share
-
Equity (Book Value)
320.94M
Book Value Per Share
2.53
Working Capital
-
Join our newsletter to keep up to date with us!
